Table 2 Prescribed treatment, supportive drugs and related outcome (n = 82)
Cate | n (%) |
|---|---|
Prescribed DAAs | |
SOF + RBV | 10 (12.2) |
SOF + SIM ± RBV | 29 (35.4) |
SOF + LDV ± RBV | 31 (37.8) |
SOF + DCV ± RBV | 12 (14.6) |
Ribavirin | |
Yes | 49 (59.7) |
No | 33 (40.3) |
Ribavirin modification | |
None | 26 (53.1) |
Reduction | 22 (44.9) |
Suspension | 1 (2) |
Adding support drug for anaemia in patients with ribavirin | |
None | 38 (77.6) |
Folic acid | 7 (14.2) |
Erythropoietin | 2 (4.1) |
Folic acid + erythropoietin | 2 (4.1) |
Reason for stopping DAAs | |
End of treatment | 80 (97.6) |
Patient decision | 1 (1.2) |
Virological failure | 1 (1.2) |